Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures

Area of Science:

• Neuroscience
• Toxicology
• Pharmacology

Background:

• Botulism is a severe neuroparalytic syndrome caused by potent botulinum neurotoxins (BoNTs).
• BoNTs block acetylcholine release by cleaving SNARE proteins, leading to potentially fatal flaccid paralysis.
• Current treatments, like antitoxins, are limited to circulating toxins and do not address intracellular BoNT.

Purpose of the Study:

• To provide a comprehensive overview of botulism, including its history, mechanisms, clinical aspects, and current treatments.
• To highlight therapeutic gaps in botulism management.
• To review emerging preclinical interventions for botulism.

Main Methods:

• Literature review of historical recognition, BoNT structure-activity relationships, and clinical manifestations.
• Analysis of current therapeutic strategies and their limitations.
• Exploration of emerging preclinical interventions such as small molecules, antibodies, and gene-based therapies.

Main Results:

• Botulism pathogenesis involves BoNTs inhibiting neurotransmission at cholinergic terminals.
• Existing antitoxins have limited efficacy against established intracellular toxin.
• Emerging preclinical interventions show promise in addressing intracellular BoNT and offer potential for improved outcomes.

Conclusions:

• Significant therapeutic gaps exist in managing botulism, necessitating novel treatment strategies.
• Advances in structural biology and pharmacology are driving the development of next-generation botulism countermeasures.
• Further research and translational efforts are crucial to overcome challenges in developing effective botulism therapies for clinical use and biodefense.